Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 10;5:81. doi: 10.1038/s41698-021-00221-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Kinases involved in fusions in different lung cancer subtypes and the number of events in each lung cancer subtype is shown to the left of each bar. b Kinase fusions in different lung cancer subtypes and the number of events in each lung cancer subtype is shown on the left. The fusion in red is a novel kinase fusion that has not been previously reported in all cancer types. Fusions marked with * represent kinase fusions never reported in lung cancer. The ☆ showed the targetable kinase fusion and the • represent the fusion which was identified as resistance mechanism to EGFR TKI or fusion TKI. c Comparison of the prevalence of kinase fusions in ADC and SCC. The number of patients with each fusion and the total number of patients in ADC or SCC are shown on the top of each bar.